186 related articles for article (PubMed ID: 29872154)
1. HIV-1 inhibition in cells with CXCR4 mutant genome created by CRISPR-Cas9 and piggyBac recombinant technologies.
Liu S; Wang Q; Yu X; Li Y; Guo Y; Liu Z; Sun F; Hou W; Li C; Wu L; Guo D; Chen S
Sci Rep; 2018 Jun; 8(1):8573. PubMed ID: 29872154
[TBL] [Abstract][Full Text] [Related]
2. Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection.
Wang Q; Chen S; Xiao Q; Liu Z; Liu S; Hou P; Zhou L; Hou W; Ho W; Li C; Wu L; Guo D
Retrovirology; 2017 Nov; 14(1):51. PubMed ID: 29141633
[TBL] [Abstract][Full Text] [Related]
3. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection.
Hou P; Chen S; Wang S; Yu X; Chen Y; Jiang M; Zhuang K; Ho W; Hou W; Huang J; Guo D
Sci Rep; 2015 Oct; 5():15577. PubMed ID: 26481100
[TBL] [Abstract][Full Text] [Related]
4. Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing.
Knipping F; Newby GA; Eide CR; McElroy AN; Nielsen SC; Smith K; Fang Y; Cornu TI; Costa C; Gutierrez-Guerrero A; Bingea SP; Feser CJ; Steinbeck B; Hippen KL; Blazar BR; McCaffrey A; Mussolino C; Verhoeyen E; Tolar J; Liu DR; Osborn MJ
Mol Ther; 2022 Jan; 30(1):130-144. PubMed ID: 34737067
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
[TBL] [Abstract][Full Text] [Related]
6. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection.
Dudek AM; Feist WN; Sasu EJ; Luna SE; Ben-Efraim K; Bak RO; Cepika AM; Porteus MH
Cell Stem Cell; 2024 Apr; 31(4):499-518.e6. PubMed ID: 38579682
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
[TBL] [Abstract][Full Text] [Related]
8. Developmental progress of CRISPR/Cas9 and its therapeutic applications for HIV-1 infection.
Deng Q; Chen Z; Shi L; Lin H
Rev Med Virol; 2018 Sep; 28(5):e1998. PubMed ID: 30024073
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
[TBL] [Abstract][Full Text] [Related]
10. A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells.
Hultquist JF; Schumann K; Woo JM; Manganaro L; McGregor MJ; Doudna J; Simon V; Krogan NJ; Marson A
Cell Rep; 2016 Oct; 17(5):1438-1452. PubMed ID: 27783955
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 system and its applications in human hematopoietic cells.
Hu X
Blood Cells Mol Dis; 2016 Nov; 62():6-12. PubMed ID: 27736664
[TBL] [Abstract][Full Text] [Related]
12. Genetically-edited induced pluripotent stem cells derived from HIV-1-infected patients on therapy can give rise to immune cells resistant to HIV-1 infection.
Teque F; Ye L; Xie F; Wang J; Morvan MG; Kan YW; Levy JA
AIDS; 2020 Jul; 34(8):1141-1149. PubMed ID: 32287059
[TBL] [Abstract][Full Text] [Related]
13. Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies.
Wang G; Yang L; Grishin D; Rios X; Ye LY; Hu Y; Li K; Zhang D; Church GM; Pu WT
Nat Protoc; 2017 Jan; 12(1):88-103. PubMed ID: 27929521
[TBL] [Abstract][Full Text] [Related]
14. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.
Bai J; Banda N; Lee NS; Rossi J; Akkina R
Mol Ther; 2002 Dec; 6(6):770-82. PubMed ID: 12498773
[TBL] [Abstract][Full Text] [Related]
15. Genome-edited baby claim provokes international outcry.
Cyranoski D; Ledford H
Nature; 2018 Nov; 563(7733):607-608. PubMed ID: 30482929
[No Abstract] [Full Text] [Related]
16. A novel approach to block HIV-1 coreceptor CXCR4 in non-toxic manner.
Liu Y; Zhou J; Pan JA; Mabiala P; Guo D
Mol Biotechnol; 2014 Oct; 56(10):890-902. PubMed ID: 24845753
[TBL] [Abstract][Full Text] [Related]
17. Efficient Editing of the CXCR4 Locus Using Cas9 Ribonucleoprotein Complexes Stabilized with Polyglutamic Acid.
Golubev DS; Komkov DS; Shepelev MV; Mazurov DV; Kruglova NA
Dokl Biol Sci; 2023 Dec; 513(Suppl 1):S28-S32. PubMed ID: 38190037
[TBL] [Abstract][Full Text] [Related]
18. [Application progress of CRISPR/Cas9 genome editing technology in the treatment of HIV-1 infection].
Han Y; Li QW
Yi Chuan; 2016 Jan; 38(1):9-16. PubMed ID: 26787519
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4.
Zhou N; Fang J; Mukhtar M; Acheampong E; Pomerantz RJ
Gene Ther; 2004 Dec; 11(23):1703-12. PubMed ID: 15306840
[TBL] [Abstract][Full Text] [Related]
20. A human immunodeficiency virus type 1 isolate from an infected person homozygous for CCR5Delta32 exhibits dual tropism by infecting macrophages and MT2 cells via CXCR4.
Naif HM; Cunningham AL; Alali M; Li S; Nasr N; Buhler MM; Schols D; de Clercq E; Stewart G
J Virol; 2002 Apr; 76(7):3114-24. PubMed ID: 11884536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
